Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.

This review highlights the various causes and treatment options for alopecia, noting that while non-scarring types often see successful hair regrowth, scarring forms require early intervention to manage inflammatory destruction of hair follicles.

This review discusses the molecular mechanisms and therapeutic effectiveness of Janus Kinase Inhibitors for inflammatory skin diseases, suggesting these inhibitors have a rapid onset and favorable safety profile compared to conventional treatments.

This study highlights how combining genetic and environmental risk assessments could advance early screening and personalized prevention for vitiligo, given its genetic complexity and environmental interactions.

This study on alopecia areata meta-analyses highlights the risk of misleading results when ineffective, unsafe, or unapproved dosing regimens are included, recommending methodological safeguards to ensure accurate data interpretation and avoid inappropriate causal inferences.

This review examines various pharmacological options for managing alopecia areata, highlighting the effectiveness of corticosteroids for mild to moderate cases and promising results from JAK inhibitors like baricitinib for more severe forms, with additional benefits from minoxidil and potential from other treatments.

This study identified a four-gene loop as a non-invasive biomarker that selectively activates in alopecia areata, providing a precise target for JAK inhibitor treatments.

This study suggests that elevated levels of IL-17A and IL-23 in alopecia areata may play roles in disease severity and activity, providing insights into potential therapeutic targets.

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

This study investigated the mechanisms of Platycladi Cacumen in treating androgenetic alopecia, identifying potential key components and targets but found no specific targets or regulatory mechanisms.

This review integrates studies on mouse models and human clinical observations to highlight the role of immune cells in skin development and how their dysregulation leads to skin disorders, suggesting potential therapeutic pathways for skin regeneration.

The abstract does not provide any specific research findings or results, but rather serves as a promotional description for IP Innovative Publication Pvt Limited, highlighting their services and publication offerings in medical journals and related fields from Delhi, India.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.

The abstract discusses the multidisciplinary nature and advancement of dermatology and aesthetic procedures within the health sciences, emphasizing the integration of diagnostic, corrective, preventive, and therapeutic approaches, but does not provide specific study results.

This review highlights that while pharmacotherapy, including biological agents, provides varying but often partial control of hidradenitis suppurativa depending on disease severity, significant challenges and high relapse rates persist, necessitating further research for more effective treatments.

This review summarizes recent advances in nanomedicine-based therapies for psoriasis, highlighting their potential to provide targeted and sustained therapeutic effects by modulating key cellular components and signaling pathways involved in the disease, offering novel perspectives for future treatment development.

This case report documented a 20-year-old male with alopecia areata who experienced slight hair regrowth following treatment with cyclosporine and methylprednisolone, highlighting the importance of individualized treatment plans and consideration of medication side effects.

In this review, researchers examined the concentration of cortisol in scalp hair of individuals with alopecia areata to explore its relationship with disease variables, as cortisol in hair can indicate chronic stress, which may impact alopecia areata pathogenesis.

This research highlights advancements in understanding and treating psoriasis, finding that targeted therapies like IL-17 and IL-23 inhibitors show promise, but challenges such as adverse events, treatment resistance, and the need for personalized approaches remain.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

Smart microneedles using advanced tech could improve psoriasis treatment.

In this study, researchers observed that individuals with alopecia areata exhibited significant changes in scalp microbiota diversity and composition, which were linked to disease severity and inflammation markers, though it remains unclear if these microbial shifts are a cause or a result of hair loss.

This report details a six-month internship experience, split between hospital and community pharmacy settings, which enhanced practical skills and theoretical knowledge in pharmaceutical care and highlighted the pharmacist's role in ensuring safe medication use.

This article reviews treatment options for Alopecia Areata, concluding that topical corticosteroids are effective for mild cases, while systemic therapies are advised for moderate to severe cases.

The authors highlighted promising developments in JAK inhibitors as targeted treatments for skin diseases such as atopic dermatitis, psoriasis, and alopecia areata, noting their effectiveness and safety profiles. Recent advances also suggest potential for treating melanoma with these inhibitors.

Personalized care and evidence-based treatments are crucial for managing skin and hair conditions.

This study reviews the range of both conventional and unconventional treatments for Alopecia Areata, highlighting the promise of biological therapies like JAK inhibitors, but notes more research is needed to optimize treatment effectiveness and personalization.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This study found that patients with alopecia areata had significantly higher levels of circulating DNA for certain cytokines compared to healthy controls, suggesting that increased circulating DNA may be linked to hair follicle damage in these patients.